Merck's Vioxx Successor Arcoxia Gets Knockout Punch From FDA ... - Trading Markets
April 12, 2007 Turkish Press | Merck's Vioxx Successor Arcoxia Gets Knockout Punch From FDA ... Trading Markets, CA - Celebrex is approved for the treatment of osteoarthritis, adult and juvenile rheumatoid arthritis, acute and menstrual pain, ankylosing spondylitis and ... The Sordid History of Cox-2 Inhibitors FDA says proposed cox-2 drugs have to fill unmet need Doctors: Arthritis drug Arcoxia risky too |
The Sordid History of Cox-2 Inhibitors - Wired News
April 12, 2007 MSNBC | The Sordid History of Cox-2 Inhibitors Wired News - Another 4 million have rheumatoid arthritis, an autoimmune disease. For years, the major treatment for the pain and inflammation of arthritis was aspirin, ... FDA says proposed cox-2 drugs have to fill unmet need Doctors: Arthritis drug Arcoxia risky too |
New Drug Treats Type 2 Diabetes - E Canada Now
April 12, 2007 E Canada Now | New Drug Treats Type 2 Diabetes E Canada Now, Canada - Boston (eCanadaNow) - A new drug which was developed originally to treat juvenile rheumatoid arthritis may actually also lead to a possible new treatment ... |
Abbott opens biotech facility in Puerto Rico - News-Medical.net
April 12, 2007| Abbott opens biotech facility in Puerto Rico News-Medical.net, Australia - ABL is now the main production facility for HUMIRA, the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), ... Abbott Laboratories opens new $450 million Puerto Rico plant |
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP ... - PipelineReview.com (press release)
April 12, 2007| Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP ... PipelineReview.com (press release), Spain - Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer. ... Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP ... |